Total Payments
$49,184
2024 Payments
$7,730
Companies
113
Transactions
2,148
Medicare Patients
10,649
Medicare Billing
$4.2M
Payment Breakdown by Category
Food & Beverage$36,059 (73.3%)
Consulting$6,382 (13.0%)
Other$2,650 (5.4%)
Education$2,107 (4.3%)
Gifts$1,136 (2.3%)
Travel$849.52 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $36,059 | 2,041 | 73.3% |
| Consulting Fee | $6,382 | 5 | 13.0% |
| Long term medical supply or device loan | $2,597 | 29 | 5.3% |
| Education | $2,107 | 60 | 4.3% |
| Gift | $1,136 | 8 | 2.3% |
| Travel and Lodging | $849.52 | 4 | 1.7% |
| Entertainment | $53.67 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,106 | 197 | $0 (2024) |
| Amgen Inc. | $4,014 | 87 | $0 (2023) |
| GENZYME CORPORATION | $3,477 | 51 | $0 (2024) |
| Genentech USA, Inc. | $2,276 | 159 | $0 (2024) |
| Partner Therapeutics, Inc. | $1,831 | 3 | $0 (2019) |
| Janssen Biotech, Inc. | $1,640 | 80 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,623 | 86 | $0 (2024) |
| PFIZER INC. | $1,590 | 145 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,570 | 89 | $0 (2024) |
| Coherus Biosciences Inc. | $1,251 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,730 | 310 | Novartis Pharmaceuticals Corporation ($1,439) |
| 2023 | $6,346 | 281 | Regeneron Healthcare Solutions, Inc. ($417.45) |
| 2022 | $6,145 | 314 | Novartis Pharmaceuticals Corporation ($729.46) |
| 2021 | $6,170 | 280 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,349) |
| 2020 | $4,701 | 195 | Novartis Pharmaceuticals Corporation ($1,172) |
| 2019 | $5,057 | 260 | Partner Therapeutics, Inc. ($900.00) |
| 2018 | $7,223 | 252 | Amgen Inc. ($2,781) |
| 2017 | $5,812 | 256 | GENZYME CORPORATION ($2,448) |
All Payment Transactions
2,148 individual payment records from CMS Open Payments — Page 1 of 86
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.63 | General |
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $30.90 | General |
| Category: Oncology | ||||||
| 12/18/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/17/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $32.01 | General |
| 12/17/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $32.01 | General |
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.58 | General |
| 12/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $87.44 | General |
| Category: NONE | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $31.56 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.81 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $1.25 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Oncology | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Oncology | ||||||
| 12/04/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: BioOncology | ||||||
| 12/03/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $34.01 | General |
| Category: Genetically Defined Disease | ||||||
| 11/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $31.56 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 2,385 | 166,336 | $2.3M | $1.1M |
| 2022 | 38 | 2,477 | 192,090 | $1.8M | $789,155 |
| 2021 | 39 | 2,918 | 174,921 | $2.5M | $1.3M |
| 2020 | 41 | 2,869 | 169,428 | $2.0M | $961,846 |
Total Patients
10,649
Total Services
702,775
Medicare Billing
$4.2M
Procedure Codes
157
All Medicare Procedures & Services
157 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 39 | 12,960 | $324,000 | $238,136 | 73.5% |
| J1566 | Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | Office | 2023 | 11 | 3,890 | $389,000 | $235,858 | 60.6% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 11 | 2,550 | $229,500 | $143,387 | 62.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 257 | 710 | $142,000 | $90,521 | 63.7% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 2,890 | $245,650 | $64,389 | 26.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 23 | 19,586 | $117,516 | $46,195 | 39.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 367 | 515 | $82,400 | $45,336 | 55.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 65 | 425 | $125,375 | $40,193 | 32.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 91 | 614 | $55,260 | $37,540 | 67.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 68 | 86,700 | $173,400 | $33,852 | 19.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 72 | 1,048 | $55,544 | $22,017 | 39.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 340 | $42,500 | $18,001 | 42.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 98 | 328 | $41,000 | $15,233 | 37.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 281 | 1,572 | $23,580 | $11,850 | 50.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 64 | 88 | $11,000 | $8,094 | 73.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $11,750 | $7,373 | 62.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 269 | 1,095 | $9,101 | $7,056 | 77.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 30 | 138 | $20,286 | $6,528 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $9,200 | $5,226 | 56.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 81 | 389 | $13,615 | $4,001 | 29.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 33 | 108 | $8,100 | $2,262 | 27.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 19 | 134 | $5,762 | $2,048 | 35.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 15 | 15 | $3,225 | $1,834 | 56.9% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 37 | 2,020 | $80,600 | $1,652 | 2.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 137 | $4,932 | $1,558 | 31.6% |
About Dr. Rizwan Danish, MD
Dr. Rizwan Danish, MD is a Hematology & Oncology healthcare provider based in Flint, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1720076284.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rizwan Danish, MD has received a total of $49,184 in payments from pharmaceutical and medical device companies, with $7,730 received in 2024. These payments were reported across 2,148 transactions from 113 companies. The most common payment nature is "Food and Beverage" ($36,059).
As a Medicare-enrolled provider, Danish has provided services to 10,649 Medicare beneficiaries, totaling 702,775 services with total Medicare billing of $4.2M. Data is available for 4 years (2020–2023), covering 157 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Flint, MI
- Active Since 10/10/2005
- Last Updated 02/27/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1720076284
Products in Payments
- KISQALI (Drug) $4,535
- JEVTANA (Drug) $2,809
- Kyprolis (Biological) $2,795
- Leukine (Drug) $1,831
- KEYTRUDA (Biological) $1,340
- Udenyca (Biological) $1,251
- Lenvima (Drug) $1,161
- BRUKINSA (Drug) $983.08
- LIBTAYO (Biological) $838.50
- XPOVIO (Drug) $755.92
- DARZALEX (Biological) $610.02
- ZEJULA (Drug) $549.18
- ERLEADA (Drug) $545.59
- OPDIVO (Biological) $519.13
- JAKAFI (Drug) $516.92
- XTANDI (Drug) $477.60
- Cabometyx (Drug) $439.80
- GAZYVA (Biological) $425.82
- LYNPARZA (Drug) $416.52
- IBRANCE (Drug) $362.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Flint
Dr. Madan Arora, M.d, M.D
Hematology & Oncology — Payments: $141,357
Hematology & Oncology $141,357
Dr. T Singh, M.d, M.D
Hematology & Oncology — Payments: $21,772
Hematology & Oncology $21,772
Dr. Venkatasiva Peram, M.d, M.D
Hematology & Oncology — Payments: $8,211
Hematology & Oncology $8,211
Sandeep Grewal, M.d, M.D
Hematology & Oncology — Payments: $6,536
Hematology & Oncology $6,536
Khalil Katato, M.d, M.D
Hematology & Oncology — Payments: $5,240
Hematology & Oncology $5,240
Dr. Paul Adams, M.d, M.D
Hematology & Oncology — Payments: $4,207
Hematology & Oncology $4,207